Related Experiment Video
Updated: Jul 3, 2026
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
Published on: June 7, 2020
In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro
Christiane Otto1, Iris Fuchs, Helga Altmann
1Research Laboratories, Bayer Schering Pharma AG, D-13353 Berlin, Germany. christiane.otto@bayerhealthcare.com
Abstract:
Estrogen receptor (ER) ligands that are able to prevent postmenopausal bone loss, but have reduced activity in the uterus and the mammary gland might be of great value for hormone therapy. It is well established that the classical ER can activate genomic as well as nongenomic signal transduction pathways. In this study, we analyse the in vivo behaviour of ER ligands that stimulate nongenomic ER effects to the same extent as estradiol, but show clearly reduced activation of genomic ER effects in vitro. Using different readout parameters such as morphological changes, cellular proliferation, and target gene induction, we are able to demonstrate that ER ligands with reduced genomic activity in vitro show a better dissociation of bone versus uterine and mammary gland effects than estradiol that stimulates genomic and nongenomic effects to the same extent. We conclude that pathway-selective ER ligands may represent an interesting option for hormone therapy.
Insights
Selective estrogen receptor (ER) ligands that target bone without affecting the uterus or mammary glands could revolutionize hormone therapy. This study shows pathway-selective ER ligands offer a promising therapeutic approach by dissociating beneficial bone effects from adverse tissue responses.
Area of Science:
- Endocrinology
- Pharmacology
- Molecular Biology
Background:
- Estrogen receptor (ER) ligands are crucial for hormone therapy, particularly in preventing postmenopausal bone loss.
- Classical ER signaling involves both genomic and nongenomic pathways, influencing various tissues like bone, uterus, and mammary glands.
- Developing ER ligands with tissue-specific effects is a key goal for safer hormone therapy.
Purpose of the Study:
- To investigate the in vivo efficacy of ER ligands with reduced genomic activity but preserved nongenomic effects.
- To assess the potential of pathway-selective ER ligands in dissociating beneficial bone effects from adverse uterine and mammary gland responses.
Main Methods:
- In vitro analysis of ER ligand activity on genomic and nongenomic pathways.
- In vivo evaluation using parameters like morphological changes, cellular proliferation, and target gene induction.
- Comparative assessment of novel ER ligands against estradiol in preclinical models.
Main Results:
- ER ligands stimulating nongenomic ER effects similarly to estradiol but with reduced genomic activity demonstrated improved dissociation of effects.
- These selective ligands showed a better separation of bone-protective actions from uterine and mammary gland stimulation compared to estradiol.
- Pathway-selective ER ligands offer a potential therapeutic advantage by minimizing off-target tissue effects.
Conclusions:
- Pathway-selective ER ligands represent a promising strategy for hormone therapy, particularly for managing postmenopausal bone loss.
- These ligands may offer a safer alternative by selectively targeting bone while reducing risks in the uterus and mammary gland.
- Further research into selective ER modulators could lead to improved treatments with enhanced efficacy and safety profiles.
